Is aflibercept an imported drug or a domestic drug?

Aflibercept (Ziv-aflibercept) is an imported drug developed by Regeneron Pharmaceuticals. It successfully received approval from the U.S. Food and Drug Administration (FDA) in 2012 and was launched on the market under the trade name Zaltrap. Aflibercept is widely used in the medical community to treat patients with metastatic colorectal cancer (mCRC) who are resistant to oxaliplatin-containing treatment regimens or whose disease has progressed. During treatment, it is often used in combination with drugs such as fluorouracil, leucovorin, and irinotecan (FOLFIRI). Aflibercept is also classified as an anti-angiogenic drug, offering new possibilities for treating certain types of cancer.